Xarelto

Jury Awards $28 Million Xarelto Lawsuit Settlement to Indiana Couple

Xarelto lawsuit settlement award

A Philadelphia jury just awarded an Indiana couple $27.8 million in damages due to severe gastrointestinal bleeding while taking Xarelto. Plaintiff Lynn Hartman and her husband filed the lawsuit in 2015, one year after Lynn’s hospitalization for uncontrolled internal bleeding. Hartman, an atrial fibrillation (a-fib) patient, started taking blood thinner Xarelto in 2013 to prevent strokes. The Xarelto lawsuit settlement reached on December 5 includes $26 million in punitive damages and $1.8 million in compensatory damages.

SEC Filing Reveals 27% Growth in Xarelto Lawsuit Settlement Claims

More than 21,000 additional plaintiffs filed lawsuits against Xarelto’s manufacturers, Johnson & Johnson and Bayer (who jointly developed the drug). But the three previous Xarelto bellwether trials in the past year resulted in favorable rulings for both drug manufacturing companies. Hartman’s verdict is the first win for plaintiffs nationwide who joined the federal Xarelto MDL. While claims vary, most allege Xarelto’s manufacturers failed to adequately warn consumers about the drug’s dangers, including potentially fatal bleeds. According to the FDA’s adverse event reporting system, at least 370 deaths are now linked to Xarelto. Including any wrongful death suits filed on deceased victims’ behalf, Xarelto lawsuit settlement claims increased 27% for this year alone.

Former FDA Chief Testifies In Xarelto Lawsuit Settlement Case

Former U.S. Food and Drug Administration Chief David Kessler testified on Hartman’s behalf before the Philadelphia Common Pleas Court jury. During Hartman’s trial, Kessler stated that Xarelto’s warning label understated the drug’s bleeding risks. He also testified that J&J’s subsidiary, Janssen Pharmaceuticals, failed to warn doctors about higher bleed out risks for certain patients. Interestingly, in October 2016, the FDA issued updated information regarding the 2011 Xarelto ROCKET AF clinical trials. Despite a recent recall involving a faulty monitoring device used during these trials, the FDA reaffirmed Xarelto’s safety profile. The document also shows, however, that 5.6 in every 1,000 Xarelto patients (5.6%) experiences severe, uncontrolled bleeding.

Hartman, who later recovered from her injuries, required four blood transfusions to counteract Xarelto’s blood-thinning effects. Unlike other anticoagulant medications (like warfarin and Pradaxa), Xarelto has no antidote, which puts patients at risk for bleeding out. Without a reversal agent, thousands of Xarelto patients may experience internal or uncontrollable bleeding — a severe and potentially fatal complication. In Philadelphia’s federal court system alone, are nearly 1,400 Xarelto cases are still pending. Most individual Xarelto lawsuits are now consolidated under a multidistrict litigation (MDL) for the Eastern District of Louisiana.

This Xarelto lawsuit settlement marks a positive step forward for the thousands still seeking justice and compensation for their injuries.

Bayer, J&J Plan to Appeal Xarelto Lawsuit Settlement

Bayer officials issued a statement saying there was “no basis” for the verdict that resulted in Hartman’s Xarelto lawsuit settlement. Both Bayer and J&J subsidiary Janssen will file appeals seeking to overturn the ruling and $27.8 million Xarelto lawsuit settlement. And it’s easy to see why: In 2016, Xarelto was Bayer’s best-selling pharmaceutical product, earning $3.41 billion globally that year. Janssen’s parent company, Johnson & Johnson, reported $2.2 billion in Xarelto revenue for 2016, making it the company’s third-largest seller.

While defendants prevailed in the first three bellwether trials, the Hartman Xarelto lawsuit settlement proves the fight isn’t over yet. After the first May Xarelto bellwether trial ruled in the defense’s favor, Bloomberg interviewed plaintiff Joseph Boudreaux’s lawyer, Gerald Meunier. “We never expected the struggle to be an easy one,” Meunier acknowledged. “We realize Bayer and Janssen have a lot of resources and a lot of motivation to protect Xarelto.”

See If You May Qualify for a Xarelto Lawsuit Settlement

If you or a loved one experienced severe bleeding episodes while taking Xarelto, you may qualify for a cash settlement. To see in just minutes if you may qualify for compensation, fill out your free Xarelto claim evaluation form today. Since each state’s statute of limitations varies for mass tort claims, waiting too long to file could disqualify your case. Once you’ve submitted your information, an experienced lawyer will call to discuss next steps on your claim and compensation options.